ORLANDO, Fla. and DUBLIN, Jan. 23, 2015 /PRNewswire/ -- Immune Therapeutics, Inc. today announced the signing of the agreement with KRS Global Biotechnology, Inc. for the compounding, packaging and distributing of its naltrexone tablets. The tablets will be compounded for shipment in the United States.
KRS Global is a 503B FDA approved Outsourcing Facility capable of compounding naltrexone tablets in various strengths for individual patients in response to a prescription from a licensed physician.
Immune Therapeutics has exclusive proprietary and legal rights licenses and patents for Low Dose Naltrexone for the following indications: Crohn's Disease, IBS and inflammatory diseases, prostate cancer, lymph proliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, and non-Hodgkin's lymphoma, infectious diseases such as chronic herpes virus infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, Fibromyalgia, Parkinson, chronic infections due to the Epstein-Barr virus, and chronic inflammatory conditions including chronic fatigue syndrome, a treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, and those suffering from AIDS-related complex (ARC).
Seth Elliott, President and Chief Operating Officer of Immune Therapeutics, stated, "This agreement with KRS Global will help people looking to purchase a formulated product while protecting Immune Therapeutics' intellectual property. We expect that the payments to Immune Therapeutics under the agreement with KRS Global will allow the company to provide funds to Cytocom Inc. so they can complete clinical trials with the FDA for Low Dose Naltrexone in Crohn's Disease, MS, HIV/AIDS, in addition to other indications."
KRS Global is a recognized leader in pharmaceutical compounding, helping Physicians and Veterinarians with medicine precisely customized for each individual patient. Very few compounding pharmacies in the nation have implemented the quality control standards performed at its facility. Their on-site testing, sterilization and formulations allow KRS Global to provide patients with exactly what they expect to receive from their hospital; a compounded preparation that can be trusted. For more information about KRS Global visit www.GBTBIO.com.
The information contained herein is general in nature and is intended for use only as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of Low Dose Naltrexone, nor is the information intended as medical advice or diagnosis for individual health problems.
Low Dose Naltrexone has not been evaluated by the Food and Drug Administration (FDA) and is not made under the FDA's GMP requirements. It is compounded in a licensed compounding pharmacy. The compound is for the use of an individual patient who has been prescribed Low Dose Naltrexone by a licensed physician. The information contained herein is not intended for making an evaluation as to suitability, risks or benefits. Before taking any action, consult your Physician.
About Immune Therapeutics, Inc.
We are a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Our proprietary technology, therapies and patents include the treatment of a wide range of cancers. Our most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and our Low Dose Naltrexone product (LDN) or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though management considers any condition that results in altered-immune response a target for investigation, we will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
About Cytocom Inc.
Cytocom Inc. is a biotechnology company that will initially focus on developing LDN (Lodonal™) and MENK in the investigation of unmet medical needs in the areas of oncological and inflammatory diseases.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This announcement contains statements, which constitute "forward-looking statements." Forward-looking statements include any statements related to the agreement with KRS Global, and are generally identified by words such as "believe," "expect," "anticipate," "intend," "estimate," "will," "may," "continue," "should" and other similar expressions. Forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Immune Therapeutics, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking statements. As a result, recipients should not rely on such forward-looking statements. Subject to compliance with applicable law and regulations, Immune Therapeutics does not intend to update these forward-looking statements and does not undertake any obligation to do so.
Contact: Dennis S. Dobson
President and CEO
Dobson Media Group and
International Investor Relations Services Inc.
SOURCE Immune Therapeutics, Inc.